Overview of nuclides for bone pain palliation

Applied Radiation and Isotopes

Volumn 49, Issue 4, 1998, Pages 277-283

  Atkins, Harold L ^a,b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORPTION; BONE; ELECTRON EMISSION; RADIOISOTOPES;

BONE PALLIATION; RADIOPHARMACEUTICALS;

RADIOTHERAPY;

RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

BONE MARROW; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CONFERENCE PAPER; DOSIMETRY; ENERGY; HUMAN; LIFE EXPECTANCY; PRIORITY JOURNAL; RADIATION DOSE;

BONE DISEASES; HUMANS; PAIN; PALLIATIVE CARE; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 0032054461     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(97)00039-0     Document Type: Conference Paper

References (24)

1. Ackery, D. and Yardley, J. (1993) Radionuclide-targeted therapy for the management of metastatic bone pain. Seminars in Oncology 20 2, 27-31.
2. Atkins, H. L., Mausner, L. F., Srivastava, S. C. and Meinken, G. E. et al. (1993) Human biodistribution of Sn-117m(4 +)DTPA; a new agent for palliative treatment of painful osseous metastases. Radiology 186, 279-283.
3. Atkins, H. L., Mausner, L. F., Srivastava, S. C. and Meinken, G. E. et al. (1995) Tin-117m(4 +)-DTPA for palliation of pain from osseous metastases: a pilot study. Journal of Nuclear Medicine 36, 725-729.
4. Bayouth, J. E., Masey, D. J., Kasi, L. P. and Fossella, F. V. (1994) Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. Journal of Nuclear Medicine 35, 63-69.
5. Collins, C., Eary, J. F., Donaldson, G. and Vernon, C. et al. (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. Journal of Nuclear Medicine 34, 1839-1844.
6. de Klerk, J. M. H., van Dijk, A., van het Schip, A. D., Zonnenberg, B. A. and van Rijk P. P. (1992) Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. Journal of Nuclear Medicine 33, 646-651.
7. 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. Journal of Urology 116, 764-768.
8. 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. British Journal of Cancer 66, 177-180.
9. Friedell, H. L. and Storaasli, J. P. (1950) The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. American Journal of Roentgenology 64, 559-575.
10. Goeckeler, W. F., Edwards, B., Volkert, W. A., Holmes, R. A., et al. (1987) Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. Journal of Nuclear Medicine 28, 495-504.
11. Harbert, J. C. (1987) Radionuclide therapy of bone pain. In Nuclear Medicine Therapy, ed. J. C. Harbert, pp. 207-219. Thieme Medical Publishers, New York.
12. Laing, A. H., Ackery, D. M., Bayly, R. J., Buchanan, R. B., et al. (1991) Strontium-89 chloride therapy for pain palliation in prostatic skeletal malignancy. British Journal of Radiology 64, 816-822.
13. Mandel, P. R. and Chiat, H, (1962) Radioactive phosphorus for carcinoma of the breast with diffuse metastatic disease. New York State Journal of Medicine 62, 1970-1976.
14. Maxon, H. R. Iii, Schroder, L. E., Hertzberg, V. S., Thomas, S. R., et al. (1991) Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Journal of Nuclear Medicine 32, 1877-1881.
15. McEwan, A. J. B. (1994) Radiopharmaceuticals for palliative treatment of painful bone metastases. New Perspectives in Cancer Diagnosis Management 2, 24-31.
16. Mertens, W. C., Stitt, L. and Porter, A. T. (1993) Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship?. American Journal Clinical Oncology 16, 238-242.
17. Pecher, C. (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer. University of California Publications in Pharmacology 11, 117-149.
18. Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., (1993a) Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. International Journal of Radiation Oncology, Biology and Physics 25, 805-813.
19. Porter, A. T. and McEwan, A. J. B. (1993b) Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Seminar in Oncology 20 2, 38-43.
20. Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., et al. (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiotherapy and Oncology 31, 33-40.
21. Robinson, R. G., Blake, G. M., Preston, D. F., McEwan, A. J., et al. (1989) Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 9, 271-281.
22. Serafini, A., Quick, D., Houston, S., Resche, I., et al. (1996) Sm-153-EDTMP as a palliative agent for patients with bone metastases. Journal of Nuclear Medicine 37, 32(Abstract).
23. Srivastava, S. C., Meinken, G. E., Richards, P., Som, P., et al. (1985) The development and in vivo behavior of tin containing radiopharmaceuticals. I: chemistry, preparation and biodistribution in small animals. International Journal of Nuclear Medicine and Biology 12, 167-174.
24. Srivastava, S., Atkins, H., Meinken, G., Mausner, L., et al. (1995) Tin-117mDTPA for therapy of bone pain due to cancer: preliminary results. Diagnostic Oncology 4, 254.